Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Cyclo Therapeutics Inc

Healthcare US CYTH

NoneUSD
0.00(0%)

Last update at 2025-04-25T13:03:11.309518Z

Day Range

--
LowHigh

52 Week Range

0.892.57
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap38.63M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-20.03078M
  • Revenue TTM1.08M
  • Revenue Per Share TTM0.07
  • Gross Profit TTM 1.23M
  • Diluted EPS TTM-0.92

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -15.45089M -14.28665M -8.94160M -7.53253M -4.25503M
Minority interest - - - - -
Net income -15.27989M -14.30518M -8.92307M -7.67428M -4.25503M
Selling general administrative 7.81M 6.50M 3.68M 3.43M 2.43M
Selling and marketing expenses 0.01M 0.02M 0.00501M 0.00588M 0.00564M
Gross profit 1.24M 1.43M 0.84M 0.93M 0.91M
Reconciled depreciation 0.02M 0.02M 0.01M 0.00568M 0.01M
Ebit -15.61161M -14.26813M -8.96013M -7.39079M -4.25428M
Ebitda -15.75286M -14.23278M -8.96590M -7.24336M -4.24416M
Depreciation and amortization -0.14125M 0.04M -0.00577M 0.15M 0.01M
Non operating income net other - - - - -
Operating income -15.61161M -14.26813M -8.96013M -7.39079M -4.26681M
Other operating expenses 16.99M 15.85M 9.86M 8.40M 5.27M
Interest expense 0.15M 0.02M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.17100M 0.02M -0.01853M 0.14M 0.01M
Total revenue 1.38M 1.59M 0.90M 1.01M 1.01M
Total operating expenses 16.85M 15.70M 9.80M 8.32M 5.16M
Cost of revenue 0.14M 0.16M 0.07M 0.08M 0.11M
Total other income expense net 0.16M -0.01852M 0.02M -0.14175M -0.00038M
Discontinued operations - - - - -
Net income from continuing ops -15.45089M -14.28665M -8.94160M -7.53253M -4.25503M
Net income applicable to common shares -15.45089M -14.28665M -8.94160M -7.53253M -4.25503M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 13.25M 4.22M 19.52M 14.19M 4.11M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.69M 2.31M 2.06M 0.85M 0.75M
Total liab 8.49M 3.48M 3.85M 3.74M 3.18M
Total stockholder equity 4.76M 0.73M 15.67M 10.45M 0.94M
Deferred long term liab - - - - -
Other current liab 2.60M - 3.68M 3.54M 3.12M
Common stock 0.00286M 0.00085M 0.00084M 0.00048M 0.01M
Capital stock 0.00286M 0.00085M 0.00084M 0.00048M 0.01M
Retained earnings -83.85668M -63.79938M -48.34849M -34.06184M -25.12023M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00728M 0.05M 0.09M
Cash 9.25M 1.54M 16.61M 12.85M 2.78M
Cash and equivalents - - - - -
Total current liabilities 8.47M 3.48M 3.83M 3.67M 3.14M
Current deferred revenue - - - - -
Net debt -8.21348M -1.54342M -16.44172M -12.65167M -2.73121M
Short term debt 1.01M - 0.15M 0.13M 0.02M
Short long term debt - - 0.13M 0.11M -
Short long term debt total 1.03M - 0.17M 0.19M 0.05M
Other stockholder equity 88.61M 64.53M 64.02M 44.51M 26.04M
Property plant equipment - 0.06M 0.08M 0.09M 0.06M
Total current assets 12.32M 4.16M 19.44M 14.05M 3.96M
Long term investments - - - - -
Net tangible assets - 0.73M 15.67M 10.45M 0.94M
Short term investments - - - - -
Net receivables 0.12M 0.05M 0.54M 0.11M 0.18M
Long term debt - - 0.02M 0.04M -
Inventory 0.25M 0.25M 0.23M 0.24M 0.24M
Accounts payable 4.86M 3.48M 3.68M 3.54M 3.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.00048M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.04M 0.06M 0.00728M 0.05M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 0.93M 0.06M 0.08M 0.14M 0.16M
Capital lease obligations 1.03M 0.00000M 0.02M 0.04M 0.05M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.04M 0.01M -0.01405M 0.04M 0.03M
Change to liabilities -0.20039M 0.41M 0.14M 1.12M 0.90M
Total cashflows from investing activities 0.04M 0.01M -0.01405M 0.04M 0.03M
Net borrowings -0.00816M -0.00678M 0.16M 0.16M 0.16M
Total cash from financing activities 0.00678M 18.76M 18.62M 7.12M 4.10M
Change to operating activities -0.24856M -1.20297M -0.10478M -0.72888M 0.04M
Net income -15.45089M -14.28665M -8.94160M -7.53253M -4.25503M
Change in cash -15.06929M 3.77M 10.06M 0.57M 0.95M
Begin period cash flow 16.61M 12.85M 2.78M 2.22M 1.27M
End period cash flow 1.54M 16.61M 12.85M 2.78M 2.22M
Total cash from operating activities -15.11424M -15.00530M -8.54018M -6.58949M -3.18844M
Issuance of capital stock 0.00000M 18.76M 18.46M 6.99M 4.10M
Depreciation 0.02M 0.02M 0.01M 0.00568M 0.01M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.02705M 0.01M 0.00472M 0.16M 0.04M
Change to account receivables 0.43M -0.44402M 0.07M -0.06338M -0.02318M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.14458M -0.00678M 0.16M 0.13M 0.03M
Change to netincome 0.37M 0.49M 0.27M 0.43M 0.10M
Capital expenditures 0.02M 0.02M 0.05M 0.00132M 0.00296M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.04815M -1.22827M 0.12M 0.49M 0.96M
Stock based compensation 0.51M 0.47M 0.27M 0.44M 0.08M
Other non cash items -0.14825M 0.02M -9.44339M 0.01M 0.06M
Free cash flow -15.12933M -15.02780M -8.59331M -6.59081M -3.19140M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CYTH
Cyclo Therapeutics Inc		 - -% - - - 33.61 7.61 25.98 -1.3963
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Cyclo Therapeutics Inc

6714 NW 16th Street, Gainesville, FL, United States, 32653

Key Executives

Name Title Year Born
Mr. N. Scott Fine CEO & Director 1957
Mr. C. E Strattan Founder & Director 1946
Mr. Michael Eric Lisjak Chief Regulatory Officer & Sr. VP of Bus. Devel. 1973
Mr. Joshua M. Fine CFO & Sec. 1982
Dr. Jeffrey L. Tate Ph.D. COO, Chief Quality Officer & Director 1958
Mr. George L. Fails Exec. VP and Operations Mang. 1945
Ms. Lori McKenna Gorski Global Head of Patient Advocacy NA
Dr. Lise Lund Kjems M.D., Ph.D. Chief Medical Officer 1964
Mr. Joshua M. Fine CFO & Secretary 1982
Mr. Michael Eric Lisjak Global Head of Regulatory Affairs & Senior VP of Business Development 1974

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.